Not medical advice. Talk to your provider before using any peptide.
Full disclaimerPeptide Schedule Research TeamReviewed Apr 20269 Citations
PT-1417 residues (approx.)DHFRWKEach bubble = one amino acid. Size = residue mass. Color = chemical class.Uses closest standard amino acids for non-standard residues.PT-141 (bremelanotide) is the only FDA-approved peptide targeting sexual desire through MC4R activation. The RECONNECT Phase 3 trials confirmed efficacy in 1,247 women with HSDD. Nausea hits 40% of users but typically improves after the first few doses with repeat use.
500mcg · As needed
Summary: Add 2mL BAC water to your 10mg vial. Draw to 10.0 units on a U-100 syringe for a 500mcg dose. This vial will last 20 doses.
View side effects and safety warnings →
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 500mcg | As needed |
| Moderate | 1mg | As needed |
| Aggressive | 1,750mcg | As needed |
Standard reconstitution for a 10 mg vial: add 2 mL bacteriostatic water. That gives you 5,000 mcg per mL, or 5 mcg per unit on a U100 insulin syringe. At 1,750 mcg (the FDA dose), you'll draw 35 units. At 500 mcg (community test dose), draw 10 units. At 1,000 mcg, draw 20 units. You'll want ondansetron on hand for the first dose. Nausea hits hard the first time and catches people off guard. Inject 45 to 60 minutes before you need it working; don't rush this timing. One vial at this concentration gives you roughly 5 to 6 doses at 1,750 mcg or up to 20 doses at 500 mcg. Store reconstituted solution refrigerated at 2 to 8 degrees Celsius; use within 30 days. If the solution turns cloudy or shows particles, discard it. Rotate injection sites every time (abdomen and thigh are standard). Keep use to eight doses per month maximum.
Dosing based on Community off-label dosing consensus; FDA-approved Vyleesi uses different dose — 12 published references.View all sources →
Cross-check your PT-141 reconstitution math with AI
Pricing updated 2026-04-09
Prices are estimates and vary by source, location, and prescription status.Full pricing breakdown →
Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
PT-141 (bremelanotide) is the only FDA-approved peptide targeting sexual desire through MC4R activation. The RECONNECT Phase 3 trials confirmed efficacy in 1,247 women with HSDD. Nausea hits 40% of users but typically improves after the first few doses with repeat use.
